Karen S. Marder

Q: What Schools Are Affiliated With Karen S. Marder

Karen S. Marder is affiliated with the following schools: University of Minnesota, Columbia University

Karen S. Marder's AcademicInfluence.com Rankings

Karen S. Marder

Medical

#1996

World Rank

#2385

Historical Rank

Neurology

#195

World Rank

#268

Historical Rank

medical Degrees

Download Badge

Medical

Karen S. Marder's Degrees

Doctorate Medicine Columbia University

Why Is Karen S. Marder Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Karen S. Marder's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Updated research nosology for HIV-associated neurocognitive disorders (2007) (2343)
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines (2012) (1851)
Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease (1996) (1664)
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease (2014) (1591)
Unified Huntington's disease rating scale: Reliability and consistency (1996) (1393)
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. (2009) (965)
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. (2004) (713)
The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. (1998) (691)
Incidence and Predictors of Seizures in Patients with Alzheimer's Disease (2006) (509)
Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. (2000) (506)
Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease (2012) (461)
Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group (2007) (450)
Mild cognitive impairment in Parkinson disease (2010) (443)
RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk (2013) (437)
Neuropsychological detection and characterization of preclinical Alzheimer's disease (1995) (428)
HIV-associated cognitive impairment before and after the advent of combination therapy (2011) (419)
A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. (1992) (398)
The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. (1995) (384)
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. (2013) (357)
Predicting time to nursing home care and death in individuals with Alzheimer disease. (1997) (346)
The course of psychopathologic features in mild to moderate Alzheimer disease. (1997) (338)
Cognitive function in nondemented older women who took estrogen after menopause (1998) (336)
Rate of functional decline in Huntington’s disease (2000) (332)
Dementia in Parkinson's disease (1994) (313)
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG (2006) (311)
Interrater reliability of the unified Parkinson's disease rating scale motor examination (1994) (308)
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. (2015) (306)
Pooled analysis of tobacco use and risk of Parkinson disease. (2007) (306)
Clinical characteristics of a family with chromosome 17‐linked disinhibition‐dementia‐ parkinsonism‐amyotrophy complex (1994) (299)
Delusions and hallucinations are associated with worse outcome in Alzheimer disease. (2005) (296)
Dietary lipids and antioxidants in Parkinson's disease: A population‐based, case‐control study (1996) (287)
Weight loss in early stage of Huntington’s disease (2002) (284)
The frequency and associated risk factors for dementia in patients with Parkinson's disease. (1995) (280)
Genetic Aspects of Alzheimer Disease (2009) (278)
Memory and executive function impairment predict dementia in Parkinson's disease (2002) (275)
Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2 (2012) (274)
A novel human disease with abnormal prion protein sensitive to protease (2008) (270)
Age at onset of Alzheimer's disease (1994) (266)
Alzheimer's disease after remote head injury: an incidence study. (1997) (266)
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion (2012) (263)
Risk of Parkinson's disease among first-degree relatives (1996) (261)
Association of life activities with cerebral blood flow in Alzheimer disease: implications for the cognitive reserve hypothesis. (2003) (255)
Seizures in Alzheimer disease: who, when, and how common? (2009) (250)
Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia (2004) (249)
Differential effects of severe vs mild GBA mutations on Parkinson disease (2015) (246)
Association of subjective memory complaints with subsequent cognitive decline in community-dwelling elderly individuals with baseline cognitive impairment. (1997) (245)
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. (2015) (243)
Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community‐dwelling elderly persons and their first‐degree relatives (1993) (242)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease (1994) (234)
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease (2007) (232)
Research criteria for the diagnosis of prodromal dementia with Lewy bodies (2020) (232)
Distribution, type, and origin of Parkin mutations: Review and case studies (2004) (231)
A 10‐item smell identification scale related to risk for Alzheimer's disease (2005) (229)
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease (2007) (228)
Cognitive performance of GBA mutation carriers with early-onset PD (2012) (225)
An estimate of the incidence of depression in idiopathic Parkinson's disease. (1992) (220)
Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease (2003) (218)
The Columbia University Scale for Psychopathology in Alzheimer's disease. (1992) (216)
Motor signs during the course of Alzheimer disease (2004) (216)
A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. (1998) (215)
Progression of parkinsonian signs in Parkinson disease. (1999) (210)
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia (2004) (208)
An estimate of the prevalence of dementia in idiopathic Parkinson's disease. (1988) (203)
Combined effect of age and severity on the risk of dementia in Parkinson's disease (2002) (201)
Quality of Life in Patients with Alzheimer's Disease as Reported by Patient Proxies (1996) (200)
Neuropsychological characteristics of preclinical dementia in Parkinson's disease (1995) (192)
Motor signs predict poor outcomes in Alzheimer disease (2005) (189)
Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies (2014) (185)
Cortical basal ganglionic degeneration. (2001) (182)
Mortality from Parkinson disease. (1997) (176)
Incidence of and risk factors for HIV-associated distal sensory polyneuropathy (2002) (175)
Association of glucocerebrosidase mutations with dementia with lewy bodies. (2009) (175)
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease (2006) (173)
Genome-Wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population (2011) (167)
Evaluation of 50 probands with early-onset Parkinson’s disease for Parkin mutations (2002) (166)
Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study (2018) (163)
Antecedent clinical features associated with dementia in Parkinson's disease (1993) (158)
The association between Mediterranean diet adherence and Parkinson's disease (2012) (157)
Postmenopausal estrogen use and Parkinson's disease with and without dementia (1998) (156)
Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection. III. Neurologic and neuropsychological findings. (1991) (155)
Attitudes and Practices Among Internists Concerning Genetic Testing (2013) (155)
An observational study of cognitive impairment in amyotrophic lateral sclerosis. (2006) (153)
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease (2020) (153)
Motor impairment in PD (2000) (148)
An estimate of the incidence of dementia in idiopathic Parkinson's disease (1990) (148)
The effect of age of onset of PD on risk of dementia (2007) (148)
A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci (2012) (148)
Apolipoprotein E and functional recovery from brain injury following postacute rehabilitation (2000) (146)
Differences in the prevalence of essential tremor among elderly African Americans, whites, and Hispanics in northern Manhattan, NY. (1995) (142)
Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort (2009) (138)
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. (2004) (133)
Predictors of nursing home placement in Huntington disease (2003) (132)
The association of incident dementia with mortality in PD (2002) (131)
Psychopathological Features in Alzheimer's Disease: Course and Relationship with Cognitive Status (2003) (127)
Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research (2012) (126)
An Observed Performance Test of Medication Management Ability in HIV: Relation to Neuropsychological Status and Medication Adherence Outcomes (1999) (125)
Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium (2015) (125)
Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. (2010) (123)
Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations (2013) (121)
Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease (2008) (118)
Arm swing as a potential new prodromal marker of Parkinson's disease (2016) (118)
Functional significance of mild cognitive impairment in elderly patients without a dementia diagnosis. (1999) (116)
Polyamine pathway contributes to the pathogenesis of Parkinson disease (2010) (115)
Different brain networks mediate task performance in normal aging and AD (2000) (115)
Altered systemic iron metabolism in Parkinson's disease (1997) (115)
Factors associated with incident human immunodeficiency virus-dementia. (2001) (115)
Neuropsychologic impairment in early HIV infection. A risk factor for work disability. (1995) (113)
Clinical correlates of action tremor in Parkinson disease. (2001) (113)
The absence of an apolipoprotein ϵ4 allele is associated with a more aggressive form of Alzheimer's disease (1997) (112)
Association between mild parkinsonian signs and mild cognitive impairment in a community (2005) (111)
Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson’s disease (2000) (111)
Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry (2017) (110)
GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder (2015) (108)
Familial aggregation of early‐ and late‐onset Parkinson's disease (2003) (108)
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. (2007) (105)
Transdermal selegiline in HIV-associated cognitive impairment: Pilot, placebo-controlled study (2000) (103)
Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment (1993) (102)
Association between the APOE genotype and psychopathologic symptoms in Alzheimer’s disease (2002) (101)
Case-control study of the parkin gene in early-onset Parkinson disease. (2006) (101)
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture (2021) (99)
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease (2011) (98)
A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease (1996) (97)
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study (2006) (96)
The apolipoprotein ϵ4 allele in Parkinson's disease with and without dementia (1994) (95)
Recommendations of the Alzheimer's Disease–Related Dementias Conference (2014) (95)
Use of Genetic Tests among Neurologists and Psychiatrists: Knowledge, Attitudes, Behaviors, and Needs for Training (2014) (94)
Pilot association study of the β‐glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity (2005) (94)
Coordination of Prehensile Forces during Precision Grip in Huntington's Disease (2000) (93)
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease (2017) (92)
Alzheimer's Disease–Related Dementias Summit 2016: National research priorities (2017) (91)
Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. (1992) (90)
Markers of immune activation and viral load in HIV-associated sensory neuropathy (2005) (89)
Multicenter Study of Predictors of Disease Course in Alzheimer Disease (the “Predictors Study”). I. Study Design, Cohort Description, and Intersite Comparisons (1993) (89)
Contribution of aging to the severity of different motor signs in Parkinson disease. (2005) (88)
Accuracy of family history data on Parkinson’s disease (2003) (88)
The validity of new memory complaints in the elderly. (1997) (87)
The Clinical Dementia Rating scale (1996) (85)
Dystonia in Huntington's disease: Prevalence and clinical characteristics (1999) (85)
A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease. (2005) (84)
Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study (2006) (83)
Reliability of spatiotemporal gait outcome measures in Huntington's disease (2005) (82)
Estrogen to treat Alzheimer’s disease: Too little, too late? (2000) (82)
Interrater reliability of extrapyramidal signs in a group assessed for dementia. (1991) (82)
Reliability of patient completion of the historical section of the unified Parkinson's disease rating scale (1996) (80)
Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations (2009) (80)
Progression in the LRRK2-Asssociated Parkinson Disease Population (2018) (80)
Energy balance in early-stage Huntington disease. (2005) (80)
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease (2015) (80)
Analysis of an early‐onset Parkinson's disease cohort for DJ‐1 mutations (2004) (78)
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. (2010) (78)
Interrater agreement in the assessment of motor manifestations of Huntington's disease (2005) (76)
Objective assessment of progression in Huntington’s disease: A 3-year follow-up study (2001) (76)
Randomized trial of the platelet-activating factor antagonist lexipafant in HIV–associated cognitive impairment (1999) (74)
Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases (2016) (74)
Dietary intake in adults at risk for Huntington disease (2009) (74)
Elevated GM3 plasma concentration in idiopathic Parkinson’s disease: A lipidomic analysis (2017) (73)
A randomized clinical trial of CPI-1189 for HIV-associated cognitive–motor impairment (2002) (72)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
Dietary iron, animal fats, and risk of Parkinson's disease. (1998) (71)
Cognitive correlates of obsessive and compulsive symptoms in Huntington's disease. (2001) (70)
Gene-Wise Association of Variants in Four Lysosomal Storage Disorder Genes in Neuropathologically Confirmed Lewy Body Disease (2015) (70)
The impact of anxiety on conversion from mild cognitive impairment to Alzheimer's disease (2009) (70)
Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. (2008) (67)
The neuropsychological profiles of mild Alzheimer's disease and questionable dementia as compared to age-related cognitive decline (2003) (67)
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers (2012) (66)
Environmental risk factors for Parkinson's disease in an urban multiethnic community (1998) (66)
Decision-Making About Reproductive Choices Among Individuals At-Risk for Huntington's Disease (2007) (66)
Longitudinal assessment of patient dependence in Alzheimer disease. (2002) (64)
SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease (2019) (64)
Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers (2015) (63)
Palliative care for people with late-stage Huntington's disease. (2001) (63)
A prospective cohort study of neuropsychological test performance in ALS (2010) (63)
Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. (2012) (62)
Risk of action tremor in relatives of tremor-dominant and postural instability gait disorder PD (2003) (62)
Are demented patients with Parkinson's disease accurately reflected in prevalence surveys? A survival analysis (1991) (62)
Participation in clinical trials and long-term outcomes in Alzheimer's disease (1997) (61)
Fall risk and gait in Parkinson's disease: The role of the LRRK2 G2019S mutation (2013) (60)
Application of a growth curve approach to modeling the progression of Alzheimer's disease. (1996) (59)
Statistical Approaches to Longitudinal Data Analysis in Neurodegenerative Diseases: Huntington’s Disease as a Model (2017) (59)
A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia (2005) (58)
Event-related potentials (ERPs) during repetition priming in Alzheimer's patients and young and older controls. (1992) (58)
Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age of onset in adults. (2000) (57)
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. (2009) (56)
An overview of psychiatric symptoms in Huntington’s disease (2001) (56)
Undetectable Cerebrospinal Fluid HIV RNA and β-2 Microglobulin Do Not Indicate Inactive AIDS Dementia Complex in Highly Active Antiretroviral Therapy-Treated Patients (2005) (56)
An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. (2001) (56)
Longitudinal study of quality of life in people with advanced Alzheimer's disease. (2001) (56)
A 6‐month, randomized, double‐blind, placebo‐controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease (2011) (55)
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. (2016) (54)
HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir (2001) (54)
Disclosures of Huntington disease risk within families: Patterns of decision‐making and implications (2007) (54)
Clinical trials in HIV-associated cognitive impairment: Cognitive and functional outcomes (2001) (53)
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study (2019) (53)
Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease (2010) (53)
Prevalence of a history of shaking in persons 65 years of age and older: Diagnostic and functional correlates (1996) (53)
Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene (2015) (53)
Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial (2007) (53)
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomized trial. (2002) (53)
Familial aggregation of Alzheimer disease among whites, African Americans, and Caribbean Hispanics in northern Manhattan. (2000) (51)
Tracking motor impairments in the progression of Huntington's disease (2014) (51)
Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. (2014) (50)
A screening assessment of cognitive impairment in patients with ALS (2007) (49)
Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study (2002) (49)
Olfaction in Parkin heterozygotes and compound heterozygotes (2010) (49)
Neurologic and neuropsychological manifestations of human immunodeficiency virus infection in intravenous drug users without acquired immunodeficiency syndrome. Relationship to head injury. (1992) (48)
A standardized technique for establishing onset and duration of symptoms of Alzheimer's disease. (1995) (48)
PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease (2015) (48)
Alpha galactosidase A activity in Parkinson's disease (2018) (47)
Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. (2014) (46)
Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment (2003) (46)
Risk of Parkinson disease in carriers of parkin mutations: estimation using the kin-cohort method. (2008) (46)
Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium (2011) (46)
The Role of Routine Laboratory Studies and Neuroimaging in the Diagnosis of Dementia: A Clinicopathological Study (2000) (45)
Multicenter Study of Predictors of Disease Course in Alzheimer Disease (the “Predictors Study”). II. Neurological, Psychiatric, and Demographic Influences on Baseline Measures of Disease Severity (1993) (45)
The rate of cognitive decline and risk of reaching clinical milestones in Alzheimer disease. (2003) (44)
A pilot study of risk factors for dementia in Parkinson's disease (1990) (44)
Dietary Patterns, Physical Activity, Sleep, and Risk for Dementia and Cognitive Decline (2018) (43)
Cholinesterase inhibitors in dementia (2002) (43)
Application of the Movement Disorder Society prodromal criteria in healthy G2019S‐LRRK2 carriers (2018) (43)
Frequency of GBA Variants in Autopsy‐proven Multiple System Atrophy (2017) (43)
Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. (2007) (43)
Altered movement trajectories and force control during object transport in Huntington's disease (2001) (42)
Codon 618 variant of alzheimer amyloid gene associated with inherited cerebral hemorrhage (1991) (42)
Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers (2013) (42)
Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD (2012) (42)
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. (2019) (42)
A prospective controlled study of magnetic resonance imaging of the brain in gay men and parenteral drug users with human immunodeficiency virus infection. (1992) (42)
Neuropsychiatric characteristics of GBA-associated Parkinson disease (2016) (42)
Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. (1993) (41)
Lack of familial aggregation of Parkinson disease and Alzheimer disease. (2004) (41)
Neuropsychological Changes in a Prospectively Followed Cohort of Homosexual and Bisexual Men With and Without HIV Infection (1995) (41)
Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. (2013) (40)
Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. (2014) (40)
Disparities in the recording of Parkinson's disease on death certificates (2005) (40)
Modeling the influence of extrapyramidal signs on the progression of Alzheimer disease. (1996) (40)
Osteopontin enhances HIV replication and is increased in the brain and cerebrospinal fluid of HIV-infected individuals (2011) (39)
Clinical measurement of mobility and balance impairments in Huntington's disease: validity and responsiveness. (2009) (39)
Smoking and Parkinson's disease (2004) (39)
Comorbidities of Obsessive and Compulsive Symptoms in Huntington's Disease (2010) (39)
Frequency of parkin mutations in late‐onset Parkinson's disease (2003) (39)
Biopsy-proven isolated sarcoid meningitis. Case report. (1993) (38)
Clinical correlates of depressive symptoms in familial Parkinson's disease (2008) (37)
The relation between depression and parkin genotype: the CORE-PD study. (2011) (36)
REM sleep behavior disorder, as assessed by questionnaire, in G2019S LRRK2 mutation PD and carriers (2015) (36)
Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. (1999) (36)
Diagnosing Parkinson's disease using videotaped neurological examinations: Validity and factors that contribute to incorrect diagnoses (2002) (35)
The roles of family members, health care workers, and others in decision-making processes about genetic testing among individuals at risk for Huntington disease (2007) (35)
Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. (2012) (34)
Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker? (2014) (34)
Neurologic signs and symptoms in a cohort of homosexual men followed for 4.5 years (1995) (33)
Donepezil in patients with severe alzheimer’s disease (2006) (33)
Clinical correlates of Alzheimer's disease with and without silent radiographic abnormalities. (1995) (33)
The apolipoprotein epsilon 4 allele in Parkinson's disease with and without dementia. (1994) (33)
Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? (1997) (33)
Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset (2012) (32)
Functional correlates of mild parkinsonian signs in the community‐dwelling elderly: Poor balance and inability to ambulate independently (2006) (31)
SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease (2016) (31)
The Saitohin ‘Q7R’ polymorphism and tau haplotype in multi-ethnic Alzheimer disease and Parkinson's disease cohorts (2003) (31)
A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease (1990) (30)
Coordination of fingertip forces during precision grip in premanifest Huntington's disease (2011) (29)
Medication Management Skill in HIV: I. Evidence for Adaptation of Medication Management Strategies in People with Cognitive Impairment. II. Evidence for a Pervasive Lay Model of Medication Efficacy (2003) (29)
Neurologic consequences of HTLV-II infection in injection-drug users (1996) (29)
Prospective comparative study of the evolution of probable Alzheimer's disease and Parkinson's disease dementia (1998) (28)
Risk of human immunodeficiency virus type 1-related neurologic disease in a cohort of intravenous drug users. (1995) (28)
Characterization of the human mitochondrial aconitase gene (ACO2). (1998) (26)
Genetic and Clinical Predictors of Deep Brain Stimulation in Young‐Onset Parkinson's Disease (2016) (26)
Consistency of clinical diagnosis in a community-based longitudinal study of dementia and Alzheimer's disease (1995) (26)
Quantitative brain measurements in community-dwelling elderly persons with mild parkinsonian signs. (2008) (25)
Increased rate of sporadic and recurrent rare genic copy number variants in Parkinson's disease among Ashkenazi Jews (2013) (25)
Influence of APOE genotype on familial aggregation of AD in an urban population (1999) (25)
Heritability and genetic variance of dementia with Lewy bodies (2018) (25)
Validity of family history for the diagnosis of dementia among siblings of patients with late‐onset Alzheimer's disease (1998) (25)
Longitudinal Change in Gait and Motor Function in Pre-manifest Huntington’s Disease (2011) (25)
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (25)
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study (2010) (25)
Risk of Alzheimer’s disease in relatives of Parkinson’s disease patients with and without dementia (1999) (25)
Erratum: Multicenter study of predictors of disease course in Alzheimer disease (the 'predictors study'). II. Neurological, psychiatric, and demographic influences on baseline measures of disease severity (Alzheimer Disease and Associated Disorders (1993) 7 (22-32)) (1993) (25)
Body mass index in essential tremor. (2002) (24)
Variability in interval production is due to timing‐dependent deficits in Huntington's disease (2014) (24)
Sexual risk behavior changes among HIV+ and HIV-female injecting drug users over 4 years. (1998) (23)
Clinical assessment of mobility and balance impairments in pre-symptomatic Huntington's disease. (2009) (23)
Combined treatment with memantine/es‐citalopram for older depressed patients with cognitive impairment: a pilot study (2016) (23)
DaT-SPECT assessment depicts dopamine depletion among asymptomatic G2019S LRRK2 mutation carriers (2017) (23)
Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease. (2013) (22)
Low-dose Lithium Treatment for Agitation and Psychosis in Alzheimer Disease and Frontotemporal Dementia: A Case Series. (2017) (22)
Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease (2013) (22)
Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression (2021) (22)
A voxel‐based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease‐related G2019S LRRK2 mutation carriers (2014) (21)
Knowledge of and Interest in Genetic Results Among Parkinson Disease Patients and Caregivers (2014) (21)
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials (2020) (21)
Parkinson's disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation (2014) (21)
Selected health and lifestyle factors, cytosine‐adenine‐guanine status, and phenoconversion in Huntington's disease (2018) (21)
The parkin gene is not involved in late-onset Parkinson's disease. (2002) (20)
Views of internists towards uses of PGD. (2013) (20)
TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. (2012) (20)
Intact working memory in non‐manifesting LRRK2 carriers – an fMRI study (2016) (19)
The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease (2015) (19)
A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers (2016) (19)
Psychiatrists’ Views of the Genetic Bases of Mental Disorders and Behavioral Traits and Their Use of Genetic Tests (2014) (19)
Patterns of neuropsychological performance in Alzheimer's disease patients with and without extrapyramidal signs (1993) (19)
Sex differences in LRRK2 G2019S and idiopathic Parkinson's Disease (2017) (19)
Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene (2007) (18)
Mild Parkinsonian signs are associated with lower olfactory test scores in the community‐dwelling elderly (2008) (18)
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease (2021) (18)
COMBINING ISOTONIC REGRESSION AND EM ALGORITHM TO PREDICT GENETIC RISK UNDER MONOTONICITY CONSTRAINT. (2014) (18)
Reliability of symptom onset assessment in Parkinson's disease (1994) (18)
Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls (2019) (18)
Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists (2019) (18)
Parkinson disease and STN-DBS: cognitive effects in GBA mutation carriers. (2022) (18)
Clinical and neuropathological features of progressive supranuclear palsy in Leucine rich repeat kinase (LRRK2) G2019S mutation carriers (2018) (18)
Relationship between CAG repeat length and late-stage outcomes in Huntington’s disease (2002) (17)
Role of SCA2 mutations in early‐ and late‐onset dopa‐responsive parkinsonism (2002) (17)
The relationship between obsessive‐compulsive symptoms and PARKIN genotype: The CORE‐PD study (2015) (17)
Motor onset and diagnosis in Huntington disease using the diagnostic confidence level (2015) (16)
A comprehensive screening of copy number variability in dementia with Lewy bodies (2019) (16)
Picking away at frontotemporal dementia. (2002) (16)
Lessons from epidemiologic research about risk factors, modifiers, and progression of late onset Alzheimer's Disease in New York City at Columbia University Medical Center. (2012) (16)
Harris–Benedict equation estimations of energy needs as compared to measured 24-h energy expenditure by indirect calorimetry in people with early to mid-stage Huntington's disease (2008) (15)
Parkin-proven disease (2003) (15)
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease (2021) (15)
A comparison of cerebral SPECT abnormalities in HIV-positive homosexual men with and without cognitive impairment. (1995) (14)
Systemic iron metabolism and mortality from Parkinson's disease (1998) (14)
Developmental malformations in Huntington disease: neuropathologic evidence of focal neuronal migration defects in a subset of adult brains (2021) (14)
The TCR repertoire of α-synuclein-specific T cells in Parkinson’s disease is surprisingly diverse (2021) (14)
Linear rank tests for doubly censored data. (1995) (14)
Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs (2019) (14)
Interest in Genetic Testing in Ashkenazi Jewish Parkinson’s Disease Patients and Their Unaffected Relatives (2015) (14)
Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) (13)
Learning fast accurate movements requires intact frontostriatal circuits (2013) (13)
Risk Factors for Suicidal Ideation in People at Risk for Huntington's Disease. (2016) (13)
Memantine approved to treat moderate to severe Alzheimer’s disease (2004) (13)
Time allocation and disability in HIV infection: A correlational study (1994) (13)
Gender Differences in HIV-Related Neurological Progression in a Cohort of Injecting Drug Users Followed for 3.5 Years. (1997) (13)
HIV encephalitis simulating Huntington's disease (2005) (13)
Pharmacological frontiers in the treatment of AIDS dementia (2000) (13)
Predicting Disease Onset from Mutation Status Using Proband and Relative Data with Applications to Huntington's Disease. (2012) (13)
Acoustic Analysis of Voice and Speech Characteristics in Presymptomatic Gene Carriers of Huntington's Disease: Biomarkers for Preclinical Sign Onset? (2011) (12)
Mild parkinsonian signs and plasma homocysteine concentration in community-dwelling elderly individuals. (2007) (12)
Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled trial. (2002) (12)
1.003 FACILITATING CLINICAL RESEARCH: THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS (NINDS) AND STROKE PARKINSON'S DISEASE COMMON DATA ELEMENTS PROJECT (2012) (12)
Cognitive impairment and dementia in Parkinson's disease (2010) (12)
LRP10 in α-synucleinopathies (2018) (12)
Where do Perseverations Come From? (2003) (12)
The ever‐stimulating association of smoking and coffee and Parkinson's disease (2002) (12)
Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease (2015) (12)
Multidisciplinary baseline assessment of gay men with and without HIV infection: III. neurological and neuropsychological findings. (1991) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
Assessment of cognition in advanced AD: The test for severe impairment (1999) (12)
Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease (2019) (12)
Tritiated imipramine binding. A peripheral marker for serotonin in Parkinson's disease. (1991) (11)
Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington’s disease motor onset (2013) (11)
Cerebral single-photon emission computed tomography abnormalities in human immunodeficiency virus type 1-infected gay men without cognitive impairment. (1995) (11)
Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers (2022) (11)
Neuropsychological changes in a prospectively followed cohort of intravenous drug users with and without HIV (1996) (10)
Prevalence, Incidence, and Risk Factors for Dementia in Parkinson’s Disease (2003) (10)
Tarenflurbil in Patients with Mild Alzheimer’s Disease (2010) (10)
Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease. (2019) (10)
Development and neurodegeneration (2012) (10)
Usefulness of plasma haloperidol levels for monitoring clinical efficacy and side effects in Alzheimer patients with psychosis and behavioral dyscontrol. (2003) (10)
Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study (2019) (10)
The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study (2019) (10)
Hippocampal laminar distribution of tau relates to Alzheimer's disease and age of onset. (2014) (10)
Lack of association between cancer history and PARKIN genotype: A family based study in PARKIN/Parkinson's Families (2012) (9)
Amyotrophic lateral sclerosis is over-represented in two Huntington’s disease brain bank cohorts: further evidence to support genetic pleiotropy of pathogenic HTT gene expansion (2021) (9)
T Cell Responses to Neural Autoantigens Are Similar in Alzheimer’s Disease Patients and Age-Matched Healthy Controls (2020) (9)
Nonparametric estimation of age-at-onset distributions from censored kin-cohort data (2007) (9)
Contributions The APOE-e 4 Allele and the Risk of Alzheimer Disease Among African Americans , Whites , and Hispanics (2001) (9)
The commercial genetic testing landscape for Parkinson's disease. (2021) (8)
The commercial genetic testing landscape for Parkinson's disease. (2021) (8)
Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings (2019) (8)
Donepezil in patients with subcortical vascular cognitive impairment (2008) (8)
Time‐varying proportional odds model for mega‐analysis of clustered event times (2019) (8)
Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants (2014) (8)
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into the complex genetic architecture (2020) (7)
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium (2021) (7)
CCL3L1 gene copy number in individuals with and without HIV-associated neurocognitive disorder. (2012) (7)
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. 1994. (2001) (7)
Impairment of nonverbal recognition in Alzheimer disease (2007) (7)
Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. (2020) (6)
The epidemiology of dementia in patients with Parkinson's disease. (1991) (6)
Prenatal toxicology screening for substance abuse in research: codes and consequences. (2011) (6)
Arm elevation in Huntington's disease: Dystonia or levitation? (1999) (6)
Circulating type VI collagen and undulin, in patients with kidney diseases, after kidney transplantation and on hemodialysis. (1995) (6)
Apolipoprotein E4 in Parkinson's disease (1995) (6)
Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial (2020) (6)
Serum neopterin level predicts HIV-related mortality but not progression to AIDS or development of neurological disease in gay men and parenteral drug users. (1995) (6)
Corticobasal syndrome with novel argyrophilic glial inclusions (2005) (5)
Targeted Local Support Vector Machine for Age-Dependent Classification (2014) (5)
Differences in performance on English and Hebrew versions of the MoCA in Parkinson's patients☆☆☆ (2020) (5)
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Authors' reply (2002) (5)
Quantifying Postural Control in Premanifest and Manifest Huntington Disease Using Wearable Sensors (2020) (5)
Statistical modeling of Huntington disease onset. (2017) (5)
Efficient Estimation of Nonparametric Genetic Risk Function with Censored Data. (2015) (5)
Importance of Symptomatic Cerebral Infarcts on Cognitive Performance in Patients with Alzheimer's Disease (2011) (4)
Age Specific Penetrance of the LRRK2 G2019S Mutation in the Michael J Fox Ashkenazi Jewish (AJ) LRRK2 Consortium (S17.002) (2014) (4)
Genome-wide association studies of LRRK2 modifiers of Parkinson's disease (2020) (4)
RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk (2013) (4)
Huntington's disease. (2003) (4)
Comparison of medical conditions and neurological examination in early Alzheimer's disease and normal elderly. (1992) (4)
The distribution and density of Huntingtin inclusions across the Huntington disease neocortex: regional correlations with Huntingtin repeat expansion independent of pathologic grade (2022) (4)
Vitamin E and donepezil for the treatment of mild cognitive impairment (2005) (4)
Estimation of genetic risk function with covariates in the presence of missing genotypes (2017) (3)
Frequency and profile of mild cognitive impairment in Parkinson's disease: A multicentre meta-analysis of neuropsychological data (2009) (3)
Milk consumption and the risk of nigral degeneration (2016) (3)
Vaccine trial in Alzheimer’s disease is halted (2003) (3)
Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (2022) (3)
ROBUST MIXED EFFECTS MODEL FOR CLUSTERED FAILURE TIME DATA: APPLICATION TO HUNTINGTON'S DISEASE EVENT MEASURES. (2017) (3)
Predictive testing for neurodegenerative diseases in the age of next‐generation sequencing (2020) (3)
Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes. (2018) (3)
Estimating disease onset from change points of markers measured with error. (2020) (3)
Subtle neuropsychological changes in HIV+ gay men. (1990) (2)
CLINICAL “CORTICOBASAL DEGENERATION” WITH NOVEL ARGYROPHILIC GLIAL INCLUSIONS (1996) (2)
Serial MRI in HIV Infection With and Without Neurologic Impairment. (1997) (2)
Energy balance in early-stage Huntington disease 1 – 3 (2005) (2)
Dementia with Lewy Bodies: Putative clinical and genetic antecedents of dementia associated with Parkinson's disease (1996) (2)
Interater reliability and factor structure of the Unified Parkinson's Disease rating Scale motor examination. (1992) (2)
Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation: A Pilot Study (2018) (2)
Cognitive impairment in non-demented patients with Parkinson’s disease (2010) (2)
A tale of two etiologies: Loss and recovery of olfactory function (2008) (2)
Combining human and machine intelligence for clinical trial eligibility querying (2022) (2)
Who, When, and How Common? (2009) (2)
Reply to: Cognitive Effects of Deep Brain Stimulation in GBA‐Related Parkinson's Disease (2022) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
Physical activity and exercise outcomes in Huntington's disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington's disease. (2022) (2)
Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identiﬁes associated haplotypes (2014) (2)
Olfactory deficits in mold cognitive impairment predict Alzheimer's disease on follow-up (2000) (2)
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting (2021) (1)
Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant (2022) (1)
Time-varying Hazards Model for Incorporating Irregularly Measured, High-Dimensional Biomarkers. (2020) (1)
Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial (2021) (1)
Increased substantia nigra echogenicity in LRRK2 family members without mutations (2018) (1)
Assessing dependence, a unique feature of functional decline in Alzheimer's disease. (1992) (1)
The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation. (2019) (1)
Epidemiology, diagnosis, and correlates of mild cognitive impairment in Parkinson’s disease (2015) (1)
Methodological issues in the assessment of human immunodeficiency virus-related cognitive impairment. (1992) (1)
Glucocerebrosidase activity in Parkinson disease with and without GBA mutations (S7.003) (2015) (1)
CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease (2015) (1)
Early Clinical Predictors of Treatment‐Resistant and Functional Outcomes in Parkinson's Disease (2016) (1)
Reply to: No Evidence that Glucosylsphingosine Is a Biomarker for Parkinson Disease (2022) (1)
GBA Mutations in REM Sleep Behavior Disorder and Parkinson’s Disease (S19.007) (2016) (1)
Neurological and neuropsychological aspects of HIV infection (1991) (1)
The Absence of an Apolipoprotein E 4 Allele Is Associated with a More Aggressive Form of Alzheimer ' s Disease (2013) (1)
A reliable standardized technique for dating the onset of Alzheimer's disease. (1992) (1)
Outcomes and clinical correlates of Alzheimer's disease patients with "silent" stroke. (1992) (1)
Visual Perception Test Predicts a Pathological Diagnosis of Alzheimer’s Disease in Patients Presenting with Corticobasal Syndrome (P3.202) (2014) (1)
Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists (2019) (1)
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort (2023) (1)
Response to Hill‐Burns et al. letter: An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson’s disease (2011) (1)
P1-230: Frontal infarcts are associated with executive and language impairments in patients with Alzheimer's disease (2008) (0)
A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers (2016) (0)
Hippocampal Laminar Distribution of Phospho-Tau Relates to Alzheimer’s Disease and Age of Death (P1.247) (2014) (0)
Cognitive function in normal individuals with subtle extrapyramidal signs resembles that of patients with Parkinson's disease. (1992) (0)
Optimizing Clinical Research Eligibility Prescreening: An Iterative Usability Evaluation of an NLP-driven Cohort Identification Tool (2022) (0)
Epilogue (2004) (0)
Investigating the genetic architecture of Dementia with Lewy bodies: a genome-wide association study (2018) (0)
Frequency of Known Genetic Variants for Parkinson’s Disease in the PD GENEration Study Cohort (S42.002) (2023) (0)
Does Mediterranean Diet Modify Phenoconversion in Huntington's Disease (HD) ? (P07.211) (2013) (0)
RELATIONSHIP BETWEEN PD PHENOTYPES AND GENETIC AND ENVIRONMENTAL RISKS (2004) (0)
Poster 13: Huntington's Disease Disrupts Motor Control Mechanisms That Rely on Internal Models (2010) (0)
Reply: More than a co-incidence? Exploring the increased frequency of amyotrophic lateral sclerosis in Huntington disease (2022) (0)
Evidence for increased completed suicide in first-degree relatives of LRRK2 G2019S mutation Parkinson’s disease (2018) (0)
Reply from the Authors (1997) (0)
Clinical and Genetic Characteristics of Participants with Juvenile PD: The CORE-PD Study (IN10-2.001) (2012) (0)
in a Group Assessed for Dementia (2016) (0)
Corrigendum: T Cell Responses to Neural Autoantigens Are Similar in Alzheimer's Disease Patients and Age-Matched Healthy Controls (2021) (0)
Columbia University Scale for Psychopathology in Alzheimer's Disease (CUSPAD) 1992 (1999) (0)
Genome-wide association analysis of Dementia with Lewy bodies reveals unique genetic architecture (2017) (0)
Preface (2010) (0)
A Data-Driven Approach to Optimizing Clinical Study Eligibility Criteria. (2023) (0)
Quantitative Brain Measures in the Community-Dwelling Elderly with Mild Parkinsonian Signs (2010) (0)
Parkinson Disease Phenotype in Ashkenazi Jews with and without LRRK2 Mutations (IN2-2.001) (2013) (0)
Neuropsychological characteristics of weclinical dementia in A Parkinson ’ s disease (0)
Tools for communicating risk for Parkinson’s disease (2022) (0)
Third Annual Huntington Disease Clinical Research Symposium : Organized by the Huntington Study Group (Huntington Study Group Abstracts) (2010) (0)
Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset (2012) (0)
A logistic mortality risk model for seropositive gay men with neurological manifestations. (1992) (0)
Cholinesterase inhibitors in dementia (2002) (0)
Correction: Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study (2019) (0)
Author response for "The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study" (2019) (0)
Alzheimer's disease after remoteheadinjury: an incidence study (1997) (0)
Impact of IMPACT: Longitudinal Analysis of an Integrated Participant Scheduling System in a Clinical Research Setting (2020) (0)
News From the Field of Neuroscience (2007) (0)
Corrigendum to “Regional vulnerability in Huntington's disease: fMRI-guided molecular analysis in patients and a mouse model of disease” [Neurobiol Dis 52 (2013) 84–93] (2013) (0)
A Case of "Prodromal" Huntington's Disease with Neuropathology (P5.296) (2015) (0)
Identification of a sex-specific genetic signature in dementia with Lewy bodies: a meta-analysis of genome-wide association studies (2022) (0)
16.8 Factors underlying gait impairments in Huntington's disease (2005) (0)
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients (S32.009) (2015) (0)
Cognitive Function Characterization Using Electronic Health Records Notes (2021) (0)
Dementia with lewy bodies. (2001) (0)
Preliminary Data Examining the Neural Substrates of Obsessive-Compulsive Symptoms in Patients With Neurodegenerative Disorders (2020) (0)
Screening for Memory Concerns at the Well‐Woman Visit (2022) (0)
188 INFLUENCE OF DUAL-TASK PERFORMANCE ON GAIT IN PRE-MANIFEST HUNTINGTON'S DISEASE (2010) (0)
REM sleep behavior disorder (RBD) may not be a promising marker for development of LRRK2 PD as measured by RBD Sleep Questionnaire (P2.150) (2015) (0)
Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings (2019) (0)
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting (2021) (0)
P1-067 Predictive utility of five neuropsychological measures in outpatients with mild cognitive impairment (2004) (0)
Estimating the Cumulative Risk of PD in Carriers of Parkin Mutations: The CORE-PD Study (PD4.007) (2012) (0)
Persistent extrapyramidal signs are a risk factor for dementia in aging. (1993) (0)
Alpha Galactosidase A Activity in Parkinson Disease (S45.005) (2018) (0)
Natural history of Huntington’s disease: evolution of modeling onset (2022) (0)
Reply to: “Could Blood Hexosylsphingosine Be a Marker for Parkinson's Disease Linked with GBA1 Mutations”? (2022) (0)
Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists (2019) (0)
The frequency of PARKIN, LRRK2, GBA in early onset Parkinson disease patients who receive deep brain stimulation (P2.148) (2015) (0)
P1-409 The risk of dementia in sertraline treated elderly patients with depression and cognitive impairment (2004) (0)
THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE (2018) (0)
Authors' replies to the comments of Koga et al. on "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease". (2020) (0)
The Effect of Parkin Mutation Status on Cognitive Functioning in EOPD Patients with Long Disease Duration: The CORE-PD Study (PD7.008) (2012) (0)
Evaluation of the cost and effectiveness of diverse recruitment methods for a genetic screening study (2019) (0)
The TCR repertoire of α-synuclein-specific T cells in Parkinson’s disease is surprisingly diverse (2021) (0)
Constructing disease onset signatures using multi-dimensional network-structured biomarkers. (2018) (0)
Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists (2019) (0)
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials (2020) (0)
Corticobasal Syndrome with TAR Binding Protein 43–Positive Oligodendrocyte Inclusions (2022) (0)
Elevated GM3 Plasma Concentration in Parkinson’s Disease: a Lipidomics Analysis (P1.006) (2017) (0)
I13 Variability In Interval Production Is Due To Timing Dependent Deficits In Early Huntington’s Disease (2014) (0)
Frontiers of science and clinical advances in quality of life in Parkinson's disease. Preface. (2010) (0)
Selected Health and Life Style Factors and Time to Phenoconversion in Huntington’s Disease (S47.003) (2014) (0)
Third Annual Huntington Disease Clinical Research Symposium (2011) (0)
Age of Onset of Huntington's Disease in Carriers of Reduced Penetrance Alleles (2021) (0)
Patient Knowledge and Attitudes towards Genetic Testing in Parkinson's Disease Subjects with Deep Brain Stimulation (2019) (0)
Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington’s disease motor onset (2013) (0)
PALLIATIVE CARE FOR PEOPLE HUNTINGTON'S DISEASE WITH LATE-STAGE (2001) (0)
Reply from the Authors (1997) (0)
Association Studies of Neuropathologically-Confirmed Cases and Controls Reveals that the PARK10 Locus is a Major Contributor to Sporadic Parkinson disease. (S7.005) (2015) (0)
Dystonia-Predominant Adult-Onset (2017) (0)
Classic Parkinson's Disease and Lewy Body Pathology Associated with a Heterozygous PARKIN Dosage Mutation (P05.055) (2013) (0)
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (0)
Neuroepidemiology Neurogenetics P 1176 " Direct " Molecular Diagnosis of Spinal Muscular Atrophy in Moldova Genetic and Clinical Analysis of Spinocerebellar Ataxia Type 8 (sca8) Repeat Expansion in Serbia Clinic-genealogical Features of Hereditary Neuropathies with Pressure Palsies, in Novokuznetsk (2002) (0)
Platform presentation—Impairments in Precision Grip Control in Pre-symptomatic Huntington's Disease (2010) (0)
Open-label Treatment Of Combined Memantine Plus Escitalopram Treatment In Elderly Depressed Patients With Cognitive Impairment (2009) (0)
Ventral Striatum Involvement In Non Manifesting Carriers Of The G2019S Mutation In The LRRK2 Gene (P6.077) (2015) (0)
Clinical research staff perceptions on a natural language processing-driven tool for eligibility prescreening: An iterative usability assessment (2023) (0)
Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
Prologue (2004) (0)
The distribution and density of Huntingtin inclusions across the Huntington disease neocortex: regional correlations with Huntingtin repeat expansion independent of pathologic grade (2022) (0)
E9 Impairment in gait speed modulation associated with functional mobility in huntington’s disease (2016) (0)
Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD (2011) (0)
Parkinson disease penetrance in patients with Gaucher disease and in glucocerebrosidase mutation carriers (2014) (0)
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease (2020) (0)
Longitudinal Patterns of Cortical Atrophy on MRI in Patients With Alzheimer Disease With and Without Lewy Body Pathology (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Karen S. Marder?

Karen S. Marder is affiliated with the following schools: